Bronchial artery embolization for the treatment of hemoptysis: permanent versus temporary embolic materials, a single center study.

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Taninokuchi Tomassoni Makoto, Perini Daniele, Porta Francesco, Braccischi Lorenzo, Zanella Sara, Basile Antonio, Modestino Francesco, Mosconi Cristina
{"title":"Bronchial artery embolization for the treatment of hemoptysis: permanent versus temporary embolic materials, a single center study.","authors":"Taninokuchi Tomassoni Makoto, Perini Daniele, Porta Francesco, Braccischi Lorenzo, Zanella Sara, Basile Antonio, Modestino Francesco, Mosconi Cristina","doi":"10.1186/s42155-025-00554-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bronchial artery embolization (BAE) is a common interventional radiology technique used to control significant bleeding from the bronchial circulation, especially in cases of severe hemoptysis or pulmonary hemorrhage. The choice of embolizing agents plays a key role in the success, recurrence of bleeding, and safety of the procedure. However, there is no consensus on the ideal embolizing agent. This study compares the efficacy, safety, and long-term outcomes of using permanent versus temporary embolizing agents in BAE.</p><p><strong>Methods: </strong>This retrospective cohort study included patients who underwent BAE at our institution from July 2006 to May 2024. Inclusion criteria encompassed patients with hemoptysis requiring intervention, complete clinical and radiological data, and BAE with either permanent (e.g., coils, PVA particles) or temporary (e.g., gelatin sponge) embolic materials. Exclusion criteria included non-bronchial causes of hemoptysis, BAE as part of a lung transplant protocol, or use of combined embolic materials. Primary outcomes included early clinical success (cessation of bleeding during the procedure and no recurrence within a week) and late clinical success (no bleeding recurrence within 6 months). Secondary outcomes focused on procedural complications, such as pneumonia, lung infarction, or bronchial ischemia.</p><p><strong>Results: </strong>This retrospective study included a total of ninety-four procedures performed in eighty-five patients (56 males, 29 females; mean age 59; age range 8-92 years) who were admitted for BAE between July 2006 and May 2024. Permanent embolic materials were used in 59 procedures (64%), in most cases were used particles and glue (39% and 21%, respectively), while temporary embolizing materials (gelatin sponge) were used in 35 procedures (37%). Statistical analysis showed a superiority in terms of clinical outcomes in favor of permanent embolic materials (p-value 0,047).</p><p><strong>Conclusions: </strong>BAE is a safe procedure for control of hemoptysis of varying etiologies and possesses high rates of immediate clinical success with few complications. In terms of embolic materials, a superiority in term of late clinical success and lower hemorrhage recurrency rate with permanent materials were clearly observed in our population, with a similar safety profile. Further studies are needed to confirm our findings and strengthen evidence.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"40"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058560/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CVIR Endovascular","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42155-025-00554-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bronchial artery embolization (BAE) is a common interventional radiology technique used to control significant bleeding from the bronchial circulation, especially in cases of severe hemoptysis or pulmonary hemorrhage. The choice of embolizing agents plays a key role in the success, recurrence of bleeding, and safety of the procedure. However, there is no consensus on the ideal embolizing agent. This study compares the efficacy, safety, and long-term outcomes of using permanent versus temporary embolizing agents in BAE.

Methods: This retrospective cohort study included patients who underwent BAE at our institution from July 2006 to May 2024. Inclusion criteria encompassed patients with hemoptysis requiring intervention, complete clinical and radiological data, and BAE with either permanent (e.g., coils, PVA particles) or temporary (e.g., gelatin sponge) embolic materials. Exclusion criteria included non-bronchial causes of hemoptysis, BAE as part of a lung transplant protocol, or use of combined embolic materials. Primary outcomes included early clinical success (cessation of bleeding during the procedure and no recurrence within a week) and late clinical success (no bleeding recurrence within 6 months). Secondary outcomes focused on procedural complications, such as pneumonia, lung infarction, or bronchial ischemia.

Results: This retrospective study included a total of ninety-four procedures performed in eighty-five patients (56 males, 29 females; mean age 59; age range 8-92 years) who were admitted for BAE between July 2006 and May 2024. Permanent embolic materials were used in 59 procedures (64%), in most cases were used particles and glue (39% and 21%, respectively), while temporary embolizing materials (gelatin sponge) were used in 35 procedures (37%). Statistical analysis showed a superiority in terms of clinical outcomes in favor of permanent embolic materials (p-value 0,047).

Conclusions: BAE is a safe procedure for control of hemoptysis of varying etiologies and possesses high rates of immediate clinical success with few complications. In terms of embolic materials, a superiority in term of late clinical success and lower hemorrhage recurrency rate with permanent materials were clearly observed in our population, with a similar safety profile. Further studies are needed to confirm our findings and strengthen evidence.

支气管动脉栓塞治疗咯血:永久性与暂时性栓塞材料,单中心研究。
背景:支气管动脉栓塞(BAE)是一种常用的介入放射学技术,用于控制支气管循环出血,特别是在严重咯血或肺出血的情况下。栓塞剂的选择对手术的成功、出血的复发和手术的安全性起着关键作用。然而,对于理想的栓塞剂尚无共识。本研究比较了在BAE中使用永久栓塞剂和临时栓塞剂的疗效、安全性和长期结果。方法:本回顾性队列研究纳入了2006年7月至2024年5月在我院接受BAE治疗的患者。纳入标准包括需要干预的咯血患者,完整的临床和放射学资料,以及具有永久性(如线圈,PVA颗粒)或临时(如明胶海绵)栓塞材料的BAE。排除标准包括非支气管原因的咯血,BAE作为肺移植方案的一部分,或使用联合栓塞材料。主要结局包括早期临床成功(术中出血停止,一周内无复发)和晚期临床成功(6个月内无出血复发)。次要结局集中于手术并发症,如肺炎、肺梗死或支气管缺血。结果:这项回顾性研究包括85例患者共94例手术(男性56例,女性29例;平均年龄59岁;年龄在8-92岁之间),在2006年7月至2024年5月期间被BAE录取。永久性栓塞材料在59例(64%)中使用,大多数情况下使用颗粒和胶水(分别为39%和21%),而临时栓塞材料(明胶海绵)在35例(37%)中使用。统计分析显示永久性栓塞材料在临床结果方面具有优势(p值为0,047)。结论:BAE是一种安全的控制各种病因咯血的方法,具有很高的临床成功率和很少的并发症。在栓子材料方面,永久性材料在晚期临床成功和较低的出血复发率方面的优势在我们的人群中被清楚地观察到,具有相似的安全性。需要进一步的研究来证实我们的发现并加强证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CVIR Endovascular
CVIR Endovascular Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
2.30
自引率
0.00%
发文量
59
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信